Anne Barbara Leuppi-Taegtmeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne Barbara Leuppi-Taegtmeyer has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Joerg Daniel Leuppi
University Institute of Internal Medicine, Cantonal Hospital Baselland, 4410 Liestal, Switzerland
12 shared publications - Maria Boesing
University Institute of Internal Medicine, Cantonal Hospital Baselland, 4410 Liestal, Switzerland
9 shared publications - Giorgia Lüthi-Corridori
University Institute of Internal Medicine, Cantonal Hospital Baselland, 4410 Liestal, Switzerland
6 shared publications Selina Späni
Hospital Pharmacy, Cantonal Hospital Baselland, Rheinstrasse 26, Liestal 4410, Switzerland
6 shared publications- Fabienne Jaun
University Institute of Internal Medicine, Cantonal Hospital Baselland, 4410 Liestal, Switzerland
4 shared publications - Philipp Schuetz
Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland
4 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (9) , 1045-1055
Incidence of Naloxone-Use Before and After Implementing Opioid Safety Measures for Patients Hospitalised on General Wards in a Swiss University Hospital
Opioids are high-risk medications that in overdose can lead to severe life-threatening or fatal adverse drug events. Inadvertent overdose is often the cause of opioid intoxication in hospitals. We introduced digital weight-based as-needed morphine and hydromorphone order sets at our hospital in November 2020 to prevent such adverse events. Naloxone given to reverse life-threatening opioid intoxication (LTOI) is a marker for these events in patient records. The main aim was to ascertain the incidence of opioid-treated patients requiring naloxone for the management of LTOI on general wards before and after implementation of the order sets. This investigator-driven, retrospective, observational, single-centre cohort study investigated naloxone administrations for LTOIs per 1000 opioid-treated patients, and per 1000 inpatients on general wards between 2019 and 2024 at the University Hospital Basel (USB). Prescription data and electronic hospital records were reviewed. During the study period, a total of 78,438 patient cases received prescription opioids, of which 149 required naloxone for LTOIs. The incidence of naloxone-treated LTOIs per 1000 opioid treated patients was 3.21 prior to the introduction of the order sets and declined to 1.46 four years later (55% reduction, p = 0.002). There were 181,314 inpatients during the study period. The incidence of naloxone per 1000 inpatients was 1.14 before and 0.64 four years after the introduction of the order sets (44% reduction, p = 0.023). We observed a significant reduction in the incidence of naloxone use for LTOI following the introduction of digital order sets for as-required morphine and hydromorphone indicating their effect to help promote safe opioid use and to improve patient safety in our hospital.
- 2 June 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (9) , 1045-1055
Open AccessIncidence of Naloxone-Use Before and After Implementing Opioid Safety Measures for Patients Hospitalised on General Wards in a Swiss University Hospital
Opioids are high-risk medications that in overdose can lead to severe life-threatening or fatal adverse drug events. Inadvertent overdose is often the cause of opioid intoxication in hospitals. We introduced digital weight-based as-needed morphine and hydromorphone order sets at our hospital in November 2020 to prevent such adverse events. Naloxone given to reverse life-threatening opioid intoxication (LTOI) is a marker for these events in patient records. The main aim was to ascertain the incidence of opioid-treated patients requiring naloxone for the management of LTOI on general wards before and after implementation of the order sets. This investigator-driven, retrospective, observational, single-centre cohort study investigated naloxone administrations for LTOIs per 1000 opioid-treated patients, and per 1000 inpatients on general wards between 2019 and 2024 at the University Hospital Basel (USB). Prescription data and electronic hospital records were reviewed. During the study period, a total of 78,438 patient cases received prescription opioids, of which 149 required naloxone for LTOIs. The incidence of naloxone-treated LTOIs per 1000 opioid treated patients was 3.21 prior to the introduction of the order sets and declined to 1.46 four years later (55% reduction, p = 0.002). There were 181,314 inpatients during the study period. The incidence of naloxone per 1000 inpatients was 1.14 before and 0.64 four years after the introduction of the order sets (44% reduction, p = 0.023). We observed a significant reduction in the incidence of naloxone use for LTOI following the introduction of digital order sets for as-required morphine and hydromorphone indicating their effect to help promote safe opioid use and to improve patient safety in our hospital.
- Open Access
- 10 May 2026
- Published by Elsevier in Toxicology Reports
- Vol. 16, 102274
Intoxication with nutmeg: A case presentation and analysis of Swiss poisons information center (Tox Info Suisse) enquiries 2014–2023
- 10 May 2026
- Published by Elsevier in Toxicology Reports
- Vol. 16, 102274
Open AccessIntoxication with nutmeg: A case presentation and analysis of Swiss poisons information center (Tox Info Suisse) enquiries 2014–2023
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 18, 1-11
Trends and Outcomes of Naloxone Use for Iatrogenic Opioid Overdose in Patients on General Wards in a Swiss Hospital: A Ten-Year Retrospective Case Series Analysis
Introduction: Opioids carry an inherent high risk of adverse drug events (ADEs), although these are generally predictable and avoidable through proper management and monitoring. Naloxone, an opioid antagonist, is used to counteract severe opioid overdoses. Aim: This study aimed to estimate the incidence of iatrogenic opioid overdoses and describe prescribing patterns before, during and after them. Methods: We conducted a ten-year retrospective case series analysis of naloxone use among inpatients at a large, multisite university hospital in Switzerland from January 2014 to December 2023. Cases were included if an adult patient had received naloxone after opioid administration and overdose. We excluded patients who received naloxone during surgery or in intensive care units. Results: Of the 671 uses of naloxone identified, 121 (18.0%) met our inclusion criteria. Yearly naloxone use incidence was 11.0 per 10,000 inpatients, increasing slightly from 2014 to 2023. The median daily opioid dose requiring naloxone was 73 morphine milligram equivalents (MME). According to the Schumock and Thornton scale criteria, we considered 82 (67.8%) of the 121 opioid overdoses to have been potentially preventable The median opioid doses received before hospital admission (29.4 MME) were higher than at discharge (15.0 MME). Nevertheless, 71 (68.3%) of 104 discharged patients were still prescribed at least one opioid. Conclusion: This study found that iatrogenic opioid overdoses were relatively uncommon. However, the considerable number of preventable opioid overdoses estimated leads us to conclude that opioid stewardship programmes should be recommended across Switzerland.
- 1 May 2026
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 18, 1-11
Open AccessTrends and Outcomes of Naloxone Use for Iatrogenic Opioid Overdose in Patients on General Wards in a Swiss Hospital: A Ten-Year Retrospective Case Series Analysis
Introduction: Opioids carry an inherent high risk of adverse drug events (ADEs), although these are generally predictable and avoidable through proper management and monitoring. Naloxone, an opioid antagonist, is used to counteract severe opioid overdoses. Aim: This study aimed to estimate the incidence of iatrogenic opioid overdoses and describe prescribing patterns before, during and after them. Methods: We conducted a ten-year retrospective case series analysis of naloxone use among inpatients at a large, multisite university hospital in Switzerland from January 2014 to December 2023. Cases were included if an adult patient had received naloxone after opioid administration and overdose. We excluded patients who received naloxone during surgery or in intensive care units. Results: Of the 671 uses of naloxone identified, 121 (18.0%) met our inclusion criteria. Yearly naloxone use incidence was 11.0 per 10,000 inpatients, increasing slightly from 2014 to 2023. The median daily opioid dose requiring naloxone was 73 morphine milligram equivalents (MME). According to the Schumock and Thornton scale criteria, we considered 82 (67.8%) of the 121 opioid overdoses to have been potentially preventable The median opioid doses received before hospital admission (29.4 MME) were higher than at discharge (15.0 MME). Nevertheless, 71 (68.3%) of 104 discharged patients were still prescribed at least one opioid. Conclusion: This study found that iatrogenic opioid overdoses were relatively uncommon. However, the considerable number of preventable opioid overdoses estimated leads us to conclude that opioid stewardship programmes should be recommended across Switzerland.
- 16 May 2025
- Published by SAGE Publications in Journal of Intensive Care Medicine
- Vol. 40 (6) , 686-690
Acute Esophageal Necrosis Associated with Alcoholic KetoacidosisA Case Report
Acute esophageal necrosis (AEN) is a rare condition associated with ischemia of the esophagus, corrosive injury by gastric fluids and reduced mucosal defense. It is also referred to as “Black Esophagus” or “Gurvit's syndrome”. Its clinical presentation is most notable for upper gastrointestinal bleeding with signs and symptoms such as abdominal or epigastric pain, nausea, vomiting, dysphagia and fever. AEN is diagnosed via esophagogastroduodenoscopy, where the cardinal finding is a circumferential black discoloration of the esophagus, usually most pronounced in the distal esophagus. The lesion usually stops abruptly at the gastroesophageal junction. AEN is usually seen in older men with multiple comorbidities (eg, cardiovascular disease, diabetes mellitus) and follows a triggering event (eg, sepsis, diabetic ketoacidosis). We describe the case of a 28-year-old man presenting with acute esophageal necrosis associated with alcoholic ketoacidosis after excessive alcohol consumption, prolonged starvation and self-reported increased intake of venlafaxine and quetiapine.
- 16 May 2025
- Published by SAGE Publications in Journal of Intensive Care Medicine
- Vol. 40 (6) , 686-690
Acute Esophageal Necrosis Associated with Alcoholic KetoacidosisA Case Report
Acute esophageal necrosis (AEN) is a rare condition associated with ischemia of the esophagus, corrosive injury by gastric fluids and reduced mucosal defense. It is also referred to as “Black Esophagus” or “Gurvit's syndrome”. Its clinical presentation is most notable for upper gastrointestinal bleeding with signs and symptoms such as abdominal or epigastric pain, nausea, vomiting, dysphagia and fever. AEN is diagnosed via esophagogastroduodenoscopy, where the cardinal finding is a circumferential black discoloration of the esophagus, usually most pronounced in the distal esophagus. The lesion usually stops abruptly at the gastroesophageal junction. AEN is usually seen in older men with multiple comorbidities (eg, cardiovascular disease, diabetes mellitus) and follows a triggering event (eg, sepsis, diabetic ketoacidosis). We describe the case of a 28-year-old man presenting with acute esophageal necrosis associated with alcoholic ketoacidosis after excessive alcohol consumption, prolonged starvation and self-reported increased intake of venlafaxine and quetiapine.
- Open Access
- 19 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 574
Diagnosis and Therapy of Community-Acquired Pneumonia in the Emergency Department: A Retrospective Observational Study and Medical Audit
Background: Despite advances in therapy, community-acquired pneumonia (CAP) is still associated with significant morbidity and mortality. Several studies conducted in different countries have reported suboptimal adherence to the guidelines. However, there are currently no available data on adherence to CAP guidelines specifically in Switzerland. Objectives: The aim of this study was to audit the quality of diagnosis and therapy of CAP at a Swiss general hospital. Methods: A retrospective, observational, single-center cohort study was conducted, including patients older than 18 years diagnosed with CAP and admitted to a medical ward throughout 2019 without prior antibiotic therapy prescribed by their general practitioner (GP). The baseline characteristics of the patients were analyzed, and the diagnostic workup and treatment were compared to the Swiss guidelines for CAP. Results: A total of 254 patients diagnosed with CAP were included in this study (median age 78 years, 51.6% males). Atypical pneumonia was diagnosed in 4% of patients, while an organism was identified in 33% of cases, with Streptococcus pneumoniae being the most frequently detected pathogen (57%). A chest image was taken in almost all patients. Documentation of respiratory rate was missing in 23% of cases. Procalcitonin was measured in 23.2% of cases. Pneumococcal and legionella urinary antigen testing was performed on approximately 90% of all patients and blood cultures were drawn in approximately 80% of patients. In 39% of cases, arterial blood gas analysis was performed. Guideline adherence for the administration of empiric antibiotics was documented/recorded in 75% of cases. Twelve different antibiotic regimens were administered, and they were mostly amoxicillin/clavulanate with or without macrolides, as suggested by the guidelines. In particular, the use of ceftriaxone was higher (19.7%) compared to the Swiss guidelines. The average length of antibiotic therapy was longer (8.2 days) compared to the guidelines (5–7 days). Oral steroid therapy was administered to 29.1% of patients, including to 75% of those diagnosed with COPD. Conclusion: Overall, guideline adherence was moderately low, especially with regards to the assessment of respiratory rate, performance of arterial blood gas analysis, and sputum collection. Regarding antibiotic therapy, the use of ceftriaxone and the length of antibiotic therapy should be reduced. Further research is needed to identify the reasons for guideline non-adherence, and to find effective measures for the improvement of guideline adherence.
- 19 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 574
Open AccessDiagnosis and Therapy of Community-Acquired Pneumonia in the Emergency Department: A Retrospective Observational Study and Medical Audit
Background: Despite advances in therapy, community-acquired pneumonia (CAP) is still associated with significant morbidity and mortality. Several studies conducted in different countries have reported suboptimal adherence to the guidelines. However, there are currently no available data on adherence to CAP guidelines specifically in Switzerland. Objectives: The aim of this study was to audit the quality of diagnosis and therapy of CAP at a Swiss general hospital. Methods: A retrospective, observational, single-center cohort study was conducted, including patients older than 18 years diagnosed with CAP and admitted to a medical ward throughout 2019 without prior antibiotic therapy prescribed by their general practitioner (GP). The baseline characteristics of the patients were analyzed, and the diagnostic workup and treatment were compared to the Swiss guidelines for CAP. Results: A total of 254 patients diagnosed with CAP were included in this study (median age 78 years, 51.6% males). Atypical pneumonia was diagnosed in 4% of patients, while an organism was identified in 33% of cases, with Streptococcus pneumoniae being the most frequently detected pathogen (57%). A chest image was taken in almost all patients. Documentation of respiratory rate was missing in 23% of cases. Procalcitonin was measured in 23.2% of cases. Pneumococcal and legionella urinary antigen testing was performed on approximately 90% of all patients and blood cultures were drawn in approximately 80% of patients. In 39% of cases, arterial blood gas analysis was performed. Guideline adherence for the administration of empiric antibiotics was documented/recorded in 75% of cases. Twelve different antibiotic regimens were administered, and they were mostly amoxicillin/clavulanate with or without macrolides, as suggested by the guidelines. In particular, the use of ceftriaxone was higher (19.7%) compared to the Swiss guidelines. The average length of antibiotic therapy was longer (8.2 days) compared to the guidelines (5–7 days). Oral steroid therapy was administered to 29.1% of patients, including to 75% of those diagnosed with COPD. Conclusion: Overall, guideline adherence was moderately low, especially with regards to the assessment of respiratory rate, performance of arterial blood gas analysis, and sputum collection. Regarding antibiotic therapy, the use of ceftriaxone and the length of antibiotic therapy should be reduced. Further research is needed to identify the reasons for guideline non-adherence, and to find effective measures for the improvement of guideline adherence.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 15
Assessing potential risk factors for metamizole-induced leukopenia
Background: Metamizole is a non-opioid analgesic agent that can rarely cause agranulocytosis, a severe form of leukopenia. Objectives: The aim of this study was to assess previously identified potential risk factors for the development of metamizole-induced leukopenia. Design: A retrospective, observational, matched case-control study was performed in a single-center setting. Methods: Patients who developed leukopenia in the setting of metamizole therapy were included as cases and matched 1:3 on the basis of age and sex to control patients who did not develop leukopenia when treated with metamizole. The data were obtained from the medical records of patients hospitalized at Cantonal Hospital Baselland between 2015 and 2020. Univariate and multivariate analyses were performed. Results: Eighty-six cases and 258 matched controls aged between 18 and 102 years were included. Fifty-seven percent were female. Previous leukopenic episodes (odds ratio (OR): 4.02, 95% CI: 1.95–8.28, p < 0.001) and a history of penicillin allergy (OR: 2.49, 95% CI: 1.03–6.03, p = 0.044) were found to be independent risk factors for metamizole-induced leukopenia. Conclusion: A history of previous leukopenic episodes and a history of penicillin allergy were confirmed as risk factors for metamizole-induced leukopenia. In our opinion, metamizole should be avoided in patients with these risk factors.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 15
Open AccessAssessing potential risk factors for metamizole-induced leukopenia
Background: Metamizole is a non-opioid analgesic agent that can rarely cause agranulocytosis, a severe form of leukopenia. Objectives: The aim of this study was to assess previously identified potential risk factors for the development of metamizole-induced leukopenia. Design: A retrospective, observational, matched case-control study was performed in a single-center setting. Methods: Patients who developed leukopenia in the setting of metamizole therapy were included as cases and matched 1:3 on the basis of age and sex to control patients who did not develop leukopenia when treated with metamizole. The data were obtained from the medical records of patients hospitalized at Cantonal Hospital Baselland between 2015 and 2020. Univariate and multivariate analyses were performed. Results: Eighty-six cases and 258 matched controls aged between 18 and 102 years were included. Fifty-seven percent were female. Previous leukopenic episodes (odds ratio (OR): 4.02, 95% CI: 1.95–8.28, p < 0.001) and a history of penicillin allergy (OR: 2.49, 95% CI: 1.03–6.03, p = 0.044) were found to be independent risk factors for metamizole-induced leukopenia. Conclusion: A history of previous leukopenic episodes and a history of penicillin allergy were confirmed as risk factors for metamizole-induced leukopenia. In our opinion, metamizole should be avoided in patients with these risk factors.
- Open Access
- 14 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (20) , 6515
The Correct Indication to Induce Labour in a Swiss Cantonal Hospital
Background: Induction of labour (IOL) is a way to stimulate the onset of labour using mechanical and pharmacological methods. IOL is one of the most frequently performed obstetric procedures worldwide. We aimed to determine compliance with guidelines and to investigate factors associated with the success of labour. Methods: In this retrospective, observational study, we analysed all induced deliveries in a Swiss hospital between January 2020 and December 2022. Results: Out of 1705 deliveries, 349 women underwent IOL, and 278 were included in this study, with an average age of 32 years (range 19–44 years). Most of the women were induced for missed deadlines (20.1%), the premature rupture of membranes (16.5%), and gestational diabetes mellitus (9.3%), and there was a good adherence to the guideline, especially with the indication and IOL monitoring (100%). However, an improvement needs to be made in measuring and documenting the Bishop score (41%). The success of labour was associated with multiparity (81.8% vs. 62.4% p = 0.001) and maternal non-obesity (73.4 vs. 54.1% p = 0.026). Conclusions: An improvement is needed in the measurement and documentation of the Bishop score. Further research is needed to confirm the found associations between parity, obesity, and the success of IOL.
- 14 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (20) , 6515
Open AccessThe Correct Indication to Induce Labour in a Swiss Cantonal Hospital
Background: Induction of labour (IOL) is a way to stimulate the onset of labour using mechanical and pharmacological methods. IOL is one of the most frequently performed obstetric procedures worldwide. We aimed to determine compliance with guidelines and to investigate factors associated with the success of labour. Methods: In this retrospective, observational study, we analysed all induced deliveries in a Swiss hospital between January 2020 and December 2022. Results: Out of 1705 deliveries, 349 women underwent IOL, and 278 were included in this study, with an average age of 32 years (range 19–44 years). Most of the women were induced for missed deadlines (20.1%), the premature rupture of membranes (16.5%), and gestational diabetes mellitus (9.3%), and there was a good adherence to the guideline, especially with the indication and IOL monitoring (100%). However, an improvement needs to be made in measuring and documenting the Bishop score (41%). The success of labour was associated with multiparity (81.8% vs. 62.4% p = 0.001) and maternal non-obesity (73.4 vs. 54.1% p = 0.026). Conclusions: An improvement is needed in the measurement and documentation of the Bishop score. Further research is needed to confirm the found associations between parity, obesity, and the success of IOL.
- Open Access
- 13 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (20) , 6513
Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease
The aim of the study was to examine the best-tolerated dose of pirfenidone, the adverse effects profile, and potential factors other than drug dose influencing the tolerability of pirfenidone in patients with fibrosing interstitial lung diseases (ILDs). We performed an observational retrospective study of 113 patients with IPF and other fibrosing ILDs treated with pirfenidone. Baseline liver function tests (LFTs) and dose escalation of pirfenidone were recorded for all patients. The best-tolerated dose was continued if the patient did not tolerate full dose (2400 mg) despite repeated dose escalation attempts. Potential risk factors such as age, height, weight, body mass index (BMI), body surface area (BSA), gender, smoking, and presence of comorbidities were analyzed between 3 groups of best-tolerated pirfenidone doses: 2400 mg/day vs. <2400 mg/day, 2400 mg/day vs. 1800 mg/day, and 2400 mg/day vs. 1200 mg/day. A total of 24 patients tolerated 2400 mg/day, and 89 patients tolerated <2400 mg/day (43 tolerated 1800 mg/day, 45 tolerated 1200 mg/day and 1 tolerated 600 mg/day). Patients who tolerated 2400 mg/day were taller and had a larger BSA as compared to those tolerating <2400 mg/day. Overall, males tolerated the drug better. Presence of comorbidities or smoking did not affect the tolerance of pirfenidone, except for the presence of cerebrovascular diseases. Various adverse effects did not have any significantly different frequencies between the compared groups. Moreover, 71.7% of patients experienced at least one side effect. 1200 mg/day was the best-tolerated dose in the majority of the patients. Male patients with a larger BSA and greater height showed better tolerability of pirfenidone overall.
- 13 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (20) , 6513
Open AccessFactors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease
The aim of the study was to examine the best-tolerated dose of pirfenidone, the adverse effects profile, and potential factors other than drug dose influencing the tolerability of pirfenidone in patients with fibrosing interstitial lung diseases (ILDs). We performed an observational retrospective study of 113 patients with IPF and other fibrosing ILDs treated with pirfenidone. Baseline liver function tests (LFTs) and dose escalation of pirfenidone were recorded for all patients. The best-tolerated dose was continued if the patient did not tolerate full dose (2400 mg) despite repeated dose escalation attempts. Potential risk factors such as age, height, weight, body mass index (BMI), body surface area (BSA), gender, smoking, and presence of comorbidities were analyzed between 3 groups of best-tolerated pirfenidone doses: 2400 mg/day vs. <2400 mg/day, 2400 mg/day vs. 1800 mg/day, and 2400 mg/day vs. 1200 mg/day. A total of 24 patients tolerated 2400 mg/day, and 89 patients tolerated <2400 mg/day (43 tolerated 1800 mg/day, 45 tolerated 1200 mg/day and 1 tolerated 600 mg/day). Patients who tolerated 2400 mg/day were taller and had a larger BSA as compared to those tolerating <2400 mg/day. Overall, males tolerated the drug better. Presence of comorbidities or smoking did not affect the tolerance of pirfenidone, except for the presence of cerebrovascular diseases. Various adverse effects did not have any significantly different frequencies between the compared groups. Moreover, 71.7% of patients experienced at least one side effect. 1200 mg/day was the best-tolerated dose in the majority of the patients. Male patients with a larger BSA and greater height showed better tolerability of pirfenidone overall.
- Open Access
- 28 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5601
Predictors of Length of Stay, Rehospitalization and Mortality in Community-Acquired Pneumonia Patients: A Retrospective Cohort Study
Background: Community-acquired pneumonia (CAP) represents one of the leading causes of hospitalization and has a substantial impact on the financial burden of healthcare. The aim of this study was to identify factors associated with the length of hospital stay (LOHS), rehospitalization and mortality of patients admitted for CAP. Methods: A retrospective cohort study was conducted with patients presenting to a Swiss public hospital between January 2019 and December 2019. Zero-truncated negative binomial and multivariable logistic regression analyses were performed to assess risk factors. Results: A total of 300 patients were analyzed (median 78 years, IQR [67.56, 85.50] and 53% males) with an average LOHS of 7 days (IQR [5.00, 9.00]). Of the 300 patients, 31.6% (97/300) were re-hospitalized within 6 months, 2.7% (8/300) died within 30 days and 11.7% (35/300) died within 1 year. The results showed that sex (IRR = 0.877, 95% CI = 0.776–0.992, p-value = 0.036), age (IRR = 1.007, 95% CI = 1.002–1.012, p-value = 0.003), qSOFA score (IRR = 1.143, 95% CI = 1.049–1.246, p-value = 0.002) and atypical pneumonia (IRR = 1.357, 95% CI = 1.012–1.819, p-value = 0.04) were predictive of LOHS. Diabetes (OR = 2.149, 95% CI = 1.104–4.172, p-value = 0.024), a higher qSOFA score (OR = 1.958, 95% CI = 1.295–3.002, p-value = 0.002) and rehabilitation after discharge (OR = 2.222, 95% CI = 1.017–4.855, p-value = 0.044) were associated with a higher chance of being re-hospitalized within 6 months, whereas mortality within 30 days and within one year were both associated with older age (OR = 1.248, 95% CI = 1.056–1.562, p-value = 0.026 and OR = 1.073, 95% CI = 1.025–1.132, p-value = 0.005, respectively) and the presence of a cancer diagnosis (OR = 32.671, 95% CI = 4.787–369.1, p-value = 0.001 and OR = 4.408, 95% CI = 1.680–11.43, p-value = 0.002, respectively). Conclusion: This study identified routinely available predictors for LOHS, rehospitalization and mortality in patients with CAP, which may further advance our understanding of CAP and thereby improve patient management, discharge planning and hospital costs.
- 28 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5601
Open AccessPredictors of Length of Stay, Rehospitalization and Mortality in Community-Acquired Pneumonia Patients: A Retrospective Cohort Study
Background: Community-acquired pneumonia (CAP) represents one of the leading causes of hospitalization and has a substantial impact on the financial burden of healthcare. The aim of this study was to identify factors associated with the length of hospital stay (LOHS), rehospitalization and mortality of patients admitted for CAP. Methods: A retrospective cohort study was conducted with patients presenting to a Swiss public hospital between January 2019 and December 2019. Zero-truncated negative binomial and multivariable logistic regression analyses were performed to assess risk factors. Results: A total of 300 patients were analyzed (median 78 years, IQR [67.56, 85.50] and 53% males) with an average LOHS of 7 days (IQR [5.00, 9.00]). Of the 300 patients, 31.6% (97/300) were re-hospitalized within 6 months, 2.7% (8/300) died within 30 days and 11.7% (35/300) died within 1 year. The results showed that sex (IRR = 0.877, 95% CI = 0.776–0.992, p-value = 0.036), age (IRR = 1.007, 95% CI = 1.002–1.012, p-value = 0.003), qSOFA score (IRR = 1.143, 95% CI = 1.049–1.246, p-value = 0.002) and atypical pneumonia (IRR = 1.357, 95% CI = 1.012–1.819, p-value = 0.04) were predictive of LOHS. Diabetes (OR = 2.149, 95% CI = 1.104–4.172, p-value = 0.024), a higher qSOFA score (OR = 1.958, 95% CI = 1.295–3.002, p-value = 0.002) and rehabilitation after discharge (OR = 2.222, 95% CI = 1.017–4.855, p-value = 0.044) were associated with a higher chance of being re-hospitalized within 6 months, whereas mortality within 30 days and within one year were both associated with older age (OR = 1.248, 95% CI = 1.056–1.562, p-value = 0.026 and OR = 1.073, 95% CI = 1.025–1.132, p-value = 0.005, respectively) and the presence of a cancer diagnosis (OR = 32.671, 95% CI = 4.787–369.1, p-value = 0.001 and OR = 4.408, 95% CI = 1.680–11.43, p-value = 0.002, respectively). Conclusion: This study identified routinely available predictors for LOHS, rehospitalization and mortality in patients with CAP, which may further advance our understanding of CAP and thereby improve patient management, discharge planning and hospital costs.
- Open Access
- 25 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5520
Is Serum 25-Hydroxyvitamin D Level Associated with Severity of COVID-19? A Retrospective Study
(1) Background: SARS-COV2 infection has a clinical spectrum ranging from asymptomatic infection to COVID-19 with acute respiratory distress syndrome (ARDS). Although vitamin D deficiency is often found in patients with ARDS, its role in COVID-19 is not clear. The aim of this study was to explore a possible association between serum 25-hydroxyvitamin D levels and the severity of COVID-19 in hospitalised patients. (2) Methods: In this retrospective observational study, we analysed data from 763 patients hospitalised for COVID-19 in 2020 and 2021. Patients were included in the study if serum 25-hydroxyvitamin D was assessed 30 days before or after hospital admission. Vitamin D deficiency was defined as p = 0.829). (4) Conclusion: No association was found between serum 25-hydroxyvitamin D levels and COVID-19 severity in this large observational study conducted over 2 years of the pandemic.
- 25 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (17) , 5520
Open AccessIs Serum 25-Hydroxyvitamin D Level Associated with Severity of COVID-19? A Retrospective Study
(1) Background: SARS-COV2 infection has a clinical spectrum ranging from asymptomatic infection to COVID-19 with acute respiratory distress syndrome (ARDS). Although vitamin D deficiency is often found in patients with ARDS, its role in COVID-19 is not clear. The aim of this study was to explore a possible association between serum 25-hydroxyvitamin D levels and the severity of COVID-19 in hospitalised patients. (2) Methods: In this retrospective observational study, we analysed data from 763 patients hospitalised for COVID-19 in 2020 and 2021. Patients were included in the study if serum 25-hydroxyvitamin D was assessed 30 days before or after hospital admission. Vitamin D deficiency was defined as p = 0.829). (4) Conclusion: No association was found between serum 25-hydroxyvitamin D levels and COVID-19 severity in this large observational study conducted over 2 years of the pandemic.